ADR Biomedical Holdings Inc. (TYO:3750)

Japan · Delayed Price · Currency is JPY

791.00

-2.00 (-0.25%)

Aug 6, 2026, 12:56 PM JST

ADR Biomedical Holdings Financials Overview

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Revenue & Profits

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Revenue	50	50	122	1,560	2,144	1,335
Revenue Growth	-59.02%	-59.02%	-92.18%	-27.24%	60.60%	-3.82%
Gross Profit	9	9	-7	1,292	1,268	859
Operating Income	-907	-907	-807	-773	-795	-462
Net Income	-396	-396	-2,140	138	-1,059	-77
Earnings Per Share	-44.35	-44.35	-239.69	15.42	-118.61	-8.72
EPS Growth	-	-	-	-	-	-

Revenue by Segment

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Medical Business	50	50	95.64	126.37	237.98	257.12
Real Asset Business	-	-	26.57	1,434	1,907	1,078
Total	50	50	122.2	1,560	2,145	1,336

Cash & Debt

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Cash & Investments	125	125	255	1,038	1,123	851
Total Debt	-	-	2,647	2,471	8,506	9,267
Net Cash (Debt)	125	125	-2,392	-1,433	-7,383	-8,416
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	14.00	14.00	-267.91	-159.95	-826.90	-953.13

Cash Flow & CapEx

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Operating Cash Flow	-784	-784	-987	-1,152	-39	-187
Capital Expenditures	-	-	-8	-17	-158	-180
Free Cash Flow	-784	-784	-995	-1,169	-197	-367
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Gross Margin	18.00%	18.00%	-5.74%	82.82%	59.14%	64.34%
Operating Margin	-1814.00%	-1814.00%	-661.48%	-49.55%	-37.08%	-34.61%
Pretax Margin	-792.00%	-792.00%	-1763.93%	-64.87%	-54.34%	-4.94%
Profit Margin	-792.00%	-792.00%	-1754.10%	8.85%	-49.39%	-5.77%
FCF Margin	-1568.00%	-1568.00%	-815.57%	-74.94%	-9.19%	-27.49%

Valuation

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Aug '26 Aug 6, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
PE Ratio	-	-	-	62.63	-	-
PS Ratio	141.60	145.35	58.69	5.54	4.72	7.75